CN113846140A - Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis - Google Patents
Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis Download PDFInfo
- Publication number
- CN113846140A CN113846140A CN202111148836.2A CN202111148836A CN113846140A CN 113846140 A CN113846140 A CN 113846140A CN 202111148836 A CN202111148836 A CN 202111148836A CN 113846140 A CN113846140 A CN 113846140A
- Authority
- CN
- China
- Prior art keywords
- abundance
- liver
- hepatitis
- flora
- cirrhosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 39
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 25
- 238000001514 detection method Methods 0.000 title claims abstract description 17
- 206010019668 Hepatic fibrosis Diseases 0.000 title abstract description 7
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 33
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims abstract description 12
- 238000012163 sequencing technique Methods 0.000 claims abstract description 10
- 241001148134 Veillonella Species 0.000 claims abstract description 9
- 241000194017 Streptococcus Species 0.000 claims abstract description 8
- 241001608234 Faecalibacterium Species 0.000 claims abstract description 5
- 241000194036 Lactococcus Species 0.000 claims abstract description 5
- 230000007882 cirrhosis Effects 0.000 claims description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 241000187747 Streptomyces Species 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 8
- 238000012317 liver biopsy Methods 0.000 abstract description 5
- 244000005709 gut microbiome Species 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 description 7
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis, and belongs to the technical field of biological medicines. The invention collects the stool sample of the chronic hepatitis B patient, carries on the sequencing of the metagenome flora, obtains the abundance value of the corresponding level Streptococcus, Lactococcus, Veillonella, Faecalibacterium; and calculating the abundance value score according to a model formula, and evaluating whether the patient has the risk of hepatic fibrosis and liver cirrhosis according to the score. Based on the flora abundance characteristics, the evaluation result of the liver fibrosis severity and the prediction of early liver related events are obtained by detecting the specific intestinal microbiota combination abundance of hepatitis B patients, and reference is provided for the further optimized monitoring and intervention strategy made by the patients; and the pain of the patient caused by multiple times of liver biopsy is also avoided.
Description
Technical Field
The invention relates to application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis, and belongs to the technical field of biological medicines.
Background
Chronic hepatitis b is still the main cause of chronic liver disease and liver related fate events (including liver cirrhosis decompensation, hepatocellular carcinoma and death) in China. About 20% to 30% of chronic hepatitis B patients develop liver-related outcome events, which is further elevated in hepatitis B-compensated cirrhosis patients. Therefore, it is very important to further develop an optimized monitoring and intervention strategy for evaluating the severity of liver fibrosis and detecting early liver-related events of hepatitis B patients.
In clinical practice, the pathological outcome of liver biopsies is currently considered to be the gold standard for assessing the severity of liver fibrosis in patients with hepatitis B. Liver biopsy, however, is an invasive test procedure, and the patient is at risk of bleeding during the procedure. Liver biopsy procedures also suffer from sampling errors and subjective interpretation of results. Also, in clinical practice, sequential or multiple biopsies are difficult to achieve in order to predict the risk of liver-related outcome events or the efficacy of antiviral therapy.
In early embryology, the liver develops from the foregut origin, anatomically and functionally complementing the gut, constituting the "gut-liver axis". In chronic infection with hepatitis b virus, gut microbes are able to activate systemic immunity. In addition, the permeability of the intestinal tract of a hepatitis B virus infected patient is changed, bacterial translocation and endotoxin load in the portal vein are increased, and immune-mediated liver injury is promoted to further cause chronic inflammation to cause liver lesion, so that the effect of the homeostatic imbalance of the intestinal flora in the chronic hepatitis B virus infection also becomes a research hotspot at home and abroad. However, no research is currently carried out on the combination of the intestinal flora and the noninvasive diagnosis of hepatitis B, so that the noninvasive diagnosis of hepatic fibrosis and cirrhosis of hepatitis B based on the abundance characteristics of the intestinal flora has certain originality.
Disclosure of Invention
The invention aims to solve the technical problem of how to perform noninvasive detection of hepatitis B, hepatic fibrosis and cirrhosis on the basis of the abundance characteristics of intestinal flora.
In order to solve the problems, the technical scheme adopted by the invention is to provide an application of detecting the abundance of intestinal flora in hepatic fibrosis and cirrhosis, wherein the detection of the abundance of the intestinal flora is to collect stool samples of patients with chronic hepatitis B and perform metagenomic flora sequencing to obtain abundance values of corresponding genera of Streptococcus, Lactococcus, Veillonella and Faecalibacterium; calculating a score according to a model formula:
5.090*Streptococcus+3.331*10^5Lactococcus+1.692*Veillonella+7.139*Faecalibacterium-0.944；
if the score is larger than 0.658, the patient is indicated to have the risk of liver fibrosis and liver cirrhosis.
The invention provides application of detecting the abundance of intestinal flora in preparing a diagnostic kit for hepatitis B, hepatic fibrosis and/or cirrhosis.
The invention provides application of detecting the abundance of intestinal flora in preparing a hepatitis B liver fibrosis and/or cirrhosis prognosis kit.
Compared with the prior art, the invention has the following beneficial effects:
the invention extracts and sequences DNA of microbial flora in human excrement of hepatitis B patients to obtain the characteristics of microbial diversity, species and abundance, and predicts hepatic fibrosis and cirrhosis based on the abundance characteristics of the microbes. Based on the abundance characteristics of flora, establishing the intestinal microbiota combination for noninvasive detection of hepatic fibrosis and cirrhosis of chronic viral hepatitis B by combining the sequencing and noninvasive detection of the intestinal flora of patients with chronic hepatitis B; the evaluation result of the liver fibrosis severity and the prediction of early liver related events are obtained by detecting the specific intestinal microbiota combination abundance of the hepatitis B patients and are used as references for establishing further optimized monitoring and intervention strategies for the patients; and the pain of the patient caused by multiple times of liver biopsy is also avoided.
Drawings
FIG. 1 is a detection ROC curve of the horizontal intestinal flora of an individual genus.
FIG. 2 is a joint detection ROC curve; detection threshold 0.658, area under ROC curve: 0.788
Detailed Description
In order to make the invention more comprehensible, preferred embodiments are described in detail below with reference to the accompanying drawings:
the invention provides an application of detecting the abundance of intestinal flora in hepatic fibrosis and cirrhosis, wherein the detection of the abundance of the intestinal flora is to collect excrement samples of patients with chronic hepatitis B and carry out metagenomic flora sequencing to obtain abundance values of corresponding levels of Streptococcus, Lactococcus, Veillonella and Faecalibacterium; calculating a score according to a model formula:
5.090*Streptococcus+3.331*10^5Lactococcus+1.692*Veillonella+7.139*Faecalibacterium-0.944；
if the score is larger than 0.658, the patient is indicated to have the risk of liver fibrosis and liver cirrhosis.
The invention provides application of detecting the abundance of intestinal flora in preparing a diagnostic kit for hepatitis B, hepatic fibrosis and/or cirrhosis.
The invention provides application of detecting the abundance of intestinal flora in preparing a hepatitis B liver fibrosis and/or cirrhosis prognosis kit.
The invention relates to a method for detecting the correlation of the abundance of intestinal flora and the specificity of hepatitis B liver fibrosis patients and hepatitis B cirrhosis patients, which comprises the following steps:
1. extracting DNA of microbial flora in feces of patients with hepatitis B (including hepatitis B liver fibrosis patients and hepatitis B cirrhosis patients) and sequencing.
2. By LEfSe analysis (LDA Effect Size analysis), intestinal flora with obvious difference in hepatitis B liver fibrosis and hepatitis B cirrhosis patients belonging to genus (genus) level is obtained through comparative analysis and is used as a detection index for predicting hepatitis B cirrhosis.
3. And respectively drawing ROC diagnosis curves of the differential bacteria to obtain a flora combination reaching the highest diagnosis efficiency.
In clinical practice, stool specimens of patients with chronic hepatitis B are easily obtained; meanwhile, with the continuous development of sequencing technology, the abundance of the flora can be rapidly and accurately quantified by metagenome sequencing at present. By combining the metagenome sequencing of excrement samples of chronic hepatitis B patients and LEfSe analysis based on flora abundance, the differential flora of the patients with different disease courses of the chronic hepatitis B can be determined, so that a model for diagnosing liver cirrhosis is constructed, and noninvasive diagnosis of the chronic hepatitis B is promoted.
Examples
FIG. 1 shows a diagnostic ROC curve for a horizontal intestinal flora;
FIG. 2 shows the combined diagnostic ROC curve: where the threshold is 0.658, the area under the ROC curve: 0.788;
in clinical practice, stool samples of patients suffering from bradykinin are collected and subjected to metagenome flora sequencing to obtain abundance values of corresponding levels of Streptococcus, Lactococcus, Veillonella and Faecalibacterium.
Calculating a score according to a joint diagnosis model formula: 5.090 Streptococcus +3.331 ^ 10^5Lactococcus +1.692 ^ Veillonella +7.139 ^ 0.944. If the combined diagnosis model index is larger than 0.658, the patient has the risk of liver fibrosis and liver cirrhosis.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.
Claims (3)
1. The application of the detection of the abundance of the intestinal flora in the liver fibrosis and the liver cirrhosis is characterized in that the detection of the abundance of the intestinal flora is to collect an excrement sample of a chronic hepatitis B patient and carry out metagenomic flora sequencing to obtain abundance values of the corresponding genera of Streptococcus, Lactococcus, Veillonella and Faecalibacterium; calculating a score according to a model formula: 5.090 Streptomyces +3.331 ^ 10^5Lactococcus +1.692 ^ Veillonella +7.139 ^ Fae calibacterium-0.944;
if the score is larger than 0.658, the patient is indicated to have the risk of liver fibrosis and liver cirrhosis.
2. The use of the detection of abundance of intestinal flora according to claim 1 in the preparation of a diagnostic kit for hepatitis b, liver fibrosis and/or cirrhosis.
3. The use of the detection of abundance of intestinal flora according to claim 1 in the preparation of a prognosis kit for hepatitis b, liver fibrosis and/or cirrhosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111148836.2A CN113846140A (en) | 2021-09-29 | 2021-09-29 | Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111148836.2A CN113846140A (en) | 2021-09-29 | 2021-09-29 | Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113846140A true CN113846140A (en) | 2021-12-28 |
Family
ID=78977044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111148836.2A Pending CN113846140A (en) | 2021-09-29 | 2021-09-29 | Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113846140A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104195145A (en) * | 2014-07-15 | 2014-12-10 | 浙江大学 | Biomarker of liver cirrhosis, and application thereof |
| CN113186310A (en) * | 2021-04-23 | 2021-07-30 | 复旦大学附属中山医院 | Method for predicting healthy aging through relative abundance of intestinal flora |
-
2021
- 2021-09-29 CN CN202111148836.2A patent/CN113846140A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104195145A (en) * | 2014-07-15 | 2014-12-10 | 浙江大学 | Biomarker of liver cirrhosis, and application thereof |
| CN113186310A (en) * | 2021-04-23 | 2021-07-30 | 复旦大学附属中山医院 | Method for predicting healthy aging through relative abundance of intestinal flora |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | Yield of EUS-guided FNA on the diagnosis of pancreatic/peripancreatic tuberculosis | |
| Biton et al. | Assessing mucosal inflammation in a DSS-induced colitis mouse model by MR colonography | |
| Hou et al. | Diagnostic value of non-invasive bio-markers for stage-specific diagnosis of hepatic fibrosis in patients with advanced schistosomiasis japonica | |
| CN112609015A (en) | Microbial marker for predicting colorectal cancer risk and application thereof | |
| CN113699260A (en) | Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis | |
| Trovato et al. | Liver and spleen transient elastography and Acoustic Radiation Force Impulse Measurements. Performance and comparison of measurements in the same area concurrently assessed for liver fibrosis by biopsy | |
| CN114381534B (en) | Fatty liver marker microorganism and application thereof | |
| CN113846140A (en) | Application of intestinal flora abundance detection in hepatic fibrosis and liver cirrhosis | |
| CN113025696A (en) | High-sensitivity detection method for hydatid cyst based on high-throughput sequencing and application | |
| CN112501280B (en) | High-sensitivity detection method for hydatid cyst based on high-throughput sequencing | |
| Feng et al. | Leucine aminopeptidase 3: a promising serum biomarker candidate for nonalcoholic steatohepatitis diagnosis | |
| CN113637760A (en) | Method for detecting methylation of free DNA in blood plasma to assist early diagnosis of ovarian cancer | |
| US20240002939A1 (en) | Methods of diagnostic of liver fibrosis | |
| CN113999922A (en) | Acute diarrhea marker microorganism and application thereof | |
| Gupta et al. | Spectrum of intrabronchial mass lesions and role of flexible bronchoscopy in their diagnosis: a series of 74 cases | |
| Wang et al. | Advances in diagnostic ultrasound techniques for assessing liver steatosis in NAFLD | |
| CN114107484B (en) | Ulcerative colitis marker gene and application thereof | |
| CN111269973A (en) | Intestinal flora microorganisms for the assessment of sexual precocity in children | |
| CN114058695B (en) | Application of urinary tract flora detection in female urinary tract calculus diagnosis | |
| WO2022107634A1 (en) | Method for assisting determination on adaptability of esophageal cancer to endoscopic therapy, method for determining adaptability of esophageal cancer to endoscopic therapy, method for collecting data for use in determination on adaptability of esophageal cancer to endoscopic therapy, method for diagnosing adaptability of esophageal cancer to endoscopic therapy, in vitro method for assisting determination on adaptability of esophageal cancer to endoscopic therapy, method for testing on adaptability of esophageal cancer to endoscopic therapy, method for diagnosing adaptability of esophageal cancer to endoscopic therapy, diagnosis kit, and method for treating esophageal cancer | |
| Alavian et al. | Prediction of liver histological lesions with biochemical markers in chronic hepatitis B patients in Iran | |
| CN113777199A (en) | Application of bile acid metabolite in feces in hepatic fibrosis and liver cirrhosis | |
| CN118621018A (en) | Methylation marker combination for detecting pantoea and application thereof | |
| CN114381507B (en) | Graves disease marker microorganism and application thereof | |
| CN113884668A (en) | Application of pyrimidine-related metabolites in feces in hepatic fibrosis and liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |